Calo Corinne A, Barrington David A, Brown Morgan, Gonzalez Lynette, Baek Jae, Huffman Allison, Benedict Jason, Backes Floor, Chambers Laura, Cohn David, Copeland Larry, Cosgrove Casey, Nagel Christa, O'Malley David, Bixel Kristin
Ohio State University Wexner Medical Center, The Ohio State University, Columbus, OH, United States.
James Cancer Hospital, Division of Gynecologic Oncology, The Ohio State University, Columbus, OH, United States.
Gynecol Oncol Rep. 2022 Jul 8;42:101040. doi: 10.1016/j.gore.2022.101040. eCollection 2022 Aug.
To evaluate the association between pre-treatment neutrophil-to-lymphocyte ratio (NLR) and survival outcomes among patients with recurrent/metastatic cervical cancer treated with PD-1/PD-L1 inhibitors.
A retrospective analysis of patients with recurrent/metastatic cervical cancer treated with PD-1/PD-L1 inhibitors from 2016 to 2021 was conducted. Progression free survival (PFS) and overall survival (OS) outcomes were assessed for patients stratified by NLR (<8 vs ≥ 8) utilizing Kaplan-Meier method. Univariable analysis was performed to compare baseline characteristics between the two groups.
A total of 49 patients were included in analysis. A majority of patients had squamous cell histology (57%), were PD-L1 positive (55%), received ≤ 1 prior lines of systemic therapy (57%), and had distant metastatic disease at the time of treatment (69%). The groups were well-balanced with respect to age, race, histology, smoking status, PD-L1 positivity, prior lines of treatment (≤1 vs > 1), prior radiation therapy, ECOG performance status, and disease distribution for patients with a NLR < 8 (n = 35) compared to those with a NLR ≥ 8 (n = 14). A pre-treatment NLR of < 8 was associated with improved survival (p < 0.01), with 57% (95% CI: 41%, 78%) probability of survival at one year compared to 26% (95% CI: 10%, 66%) for those with NLR ≥ 8. No statistically significant differences in probability of PFS at 1 year were seen between NLR < 8 compared to those with NLR ≥ 8 (p = 0.70).
Pre-treatment NLR may hold prognostic value for patients with metastatic/recurrent cervical cancer treated with PD-1/PD-L1 inhibitors, with NLR < 8 associated with improved survival.
评估接受PD-1/PD-L1抑制剂治疗的复发性/转移性宫颈癌患者治疗前中性粒细胞与淋巴细胞比值（NLR）与生存结局之间的关联。
对2016年至2021年接受PD-1/PD-L1抑制剂治疗的复发性/转移性宫颈癌患者进行回顾性分析。采用Kaplan-Meier法评估按NLR（<8 vs≥8）分层的患者的无进展生存期（PFS）和总生存期（OS）结局。进行单因素分析以比较两组之间的基线特征。
共有49例患者纳入分析。大多数患者为鳞状细胞组织学类型（57%），PD-L1阳性（55%），接受过≤1线的全身治疗（57%），且治疗时患有远处转移性疾病（69%）。与NLR≥8（n = 14）的患者相比，NLR<8（n = 35）的患者在年龄、种族、组织学类型、吸烟状况、PD-L1阳性、既往治疗线数（≤1 vs>1）、既往放疗、东部肿瘤协作组（ECOG）体能状态和疾病分布方面均衡性良好。治疗前NLR<8与生存改善相关（p<0.01），NLR<8的患者1年生存率为57%（95%CI：41%，78%），而NLR≥8的患者为26%（95%CI：10%，66%）。NLR<8与NLR≥8的患者1年PFS概率无统计学显著差异（p = 0.70）。
治疗前NLR可能对接受PD-1/PD-L1抑制剂治疗的转移性/复发性宫颈癌患者具有预后价值，NLR<8与生存改善相关。
